Laura Esteban-Cledera, Carlo Alberto Bissacco, Meritxell Pallejá-Millán, Marcela Villalobos, Felipe Villalobos
{"title":"COVID-19 疫苗与月经失调之间的关系：西班牙加泰罗尼亚地区 12-55 岁女性的回顾性队列研究。","authors":"Laura Esteban-Cledera, Carlo Alberto Bissacco, Meritxell Pallejá-Millán, Marcela Villalobos, Felipe Villalobos","doi":"10.3390/ijerph21081090","DOIUrl":null,"url":null,"abstract":"<p><p>During the rapid development of COVID-19 vaccines, concerns emerged about potential adverse effects on menstrual health. This study examines the association between COVID-19 vaccination-considering the number of doses and vaccine type-and menstrual disorders, specifically heavy menstrual bleeding (HMB) and amenorrhea (AM). Utilizing electronic health records from the Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP) database in Catalonia, Spain, the retrospective cohort included 1,172,621 vaccinated women aged 12-55 with no prior menstrual disorders observed from 27 December 2020 to 30 June 2023. The incidence rate of HMB and AM increased with the second and third doses of the vaccine. Notably, the AstraZeneca<sup>®</sup> and Janssen<sup>®</sup> vaccines were associated with higher odds of HMB (OR: 1.765, CI: 1.527-2.033; OR: 2.155, CI: 1.873-2.476, respectively) and AM (OR: 1.623, CI: 1.416-1.854; OR: 1.989, CI: 1.740-2.269, respectively) from the first to the second dose compared to Pfizer/BioNTech<sup>®</sup>. Conversely, the Moderna<sup>®</sup> vaccine appeared to offer a protective effect against HMB (OR: 0.852, CI: 0.771-0.939) and AM (OR: 0.861, CI: 0.790-0.937) between the second and third doses. These results were adjusted for potential confounders, such as age, previous COVID-19 infection, and other relevant covariates.</p>","PeriodicalId":49056,"journal":{"name":"International Journal of Environmental Research and Public Health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11354165/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain.\",\"authors\":\"Laura Esteban-Cledera, Carlo Alberto Bissacco, Meritxell Pallejá-Millán, Marcela Villalobos, Felipe Villalobos\",\"doi\":\"10.3390/ijerph21081090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>During the rapid development of COVID-19 vaccines, concerns emerged about potential adverse effects on menstrual health. This study examines the association between COVID-19 vaccination-considering the number of doses and vaccine type-and menstrual disorders, specifically heavy menstrual bleeding (HMB) and amenorrhea (AM). Utilizing electronic health records from the Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP) database in Catalonia, Spain, the retrospective cohort included 1,172,621 vaccinated women aged 12-55 with no prior menstrual disorders observed from 27 December 2020 to 30 June 2023. The incidence rate of HMB and AM increased with the second and third doses of the vaccine. Notably, the AstraZeneca<sup>®</sup> and Janssen<sup>®</sup> vaccines were associated with higher odds of HMB (OR: 1.765, CI: 1.527-2.033; OR: 2.155, CI: 1.873-2.476, respectively) and AM (OR: 1.623, CI: 1.416-1.854; OR: 1.989, CI: 1.740-2.269, respectively) from the first to the second dose compared to Pfizer/BioNTech<sup>®</sup>. Conversely, the Moderna<sup>®</sup> vaccine appeared to offer a protective effect against HMB (OR: 0.852, CI: 0.771-0.939) and AM (OR: 0.861, CI: 0.790-0.937) between the second and third doses. These results were adjusted for potential confounders, such as age, previous COVID-19 infection, and other relevant covariates.</p>\",\"PeriodicalId\":49056,\"journal\":{\"name\":\"International Journal of Environmental Research and Public Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11354165/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Environmental Research and Public Health\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.3390/ijerph21081090\",\"RegionNum\":3,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Environmental Research and Public Health","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.3390/ijerph21081090","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在 COVID-19 疫苗的快速开发过程中，人们开始担心其对月经健康的潜在不良影响。本研究探讨了接种 COVID-19 疫苗（考虑接种剂量和疫苗类型）与月经失调（尤其是月经过多 (HMB) 和闭经 (AM) ）之间的关系。这项回顾性队列研究利用西班牙加泰罗尼亚地区Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP)数据库中的电子健康记录，纳入了1,172,621名年龄在12-55岁之间、在2020年12月27日至2023年6月30日期间未出现月经紊乱的接种过疫苗的女性。HMB和AM的发病率随着第二剂和第三剂疫苗的接种而增加。值得注意的是，与辉瑞/BioNTech®相比，阿斯利康®和杨森®疫苗从第一剂到第二剂的HMB（OR：1.765，CI：1.527-2.033；OR：2.155，CI：1.873-2.476）和AM（OR：1.623，CI：1.416-1.854；OR：1.989，CI：1.740-2.269）发生几率更高。相反，Moderna®疫苗在第二剂和第三剂之间似乎对HMB（OR：0.852，CI：0.771-0.939）和AM（OR：0.861，CI：0.790-0.937）具有保护作用。这些结果已根据潜在的混杂因素（如年龄、既往 COVID-19 感染情况及其他相关协变量）进行了调整。
Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain.
During the rapid development of COVID-19 vaccines, concerns emerged about potential adverse effects on menstrual health. This study examines the association between COVID-19 vaccination-considering the number of doses and vaccine type-and menstrual disorders, specifically heavy menstrual bleeding (HMB) and amenorrhea (AM). Utilizing electronic health records from the Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP) database in Catalonia, Spain, the retrospective cohort included 1,172,621 vaccinated women aged 12-55 with no prior menstrual disorders observed from 27 December 2020 to 30 June 2023. The incidence rate of HMB and AM increased with the second and third doses of the vaccine. Notably, the AstraZeneca® and Janssen® vaccines were associated with higher odds of HMB (OR: 1.765, CI: 1.527-2.033; OR: 2.155, CI: 1.873-2.476, respectively) and AM (OR: 1.623, CI: 1.416-1.854; OR: 1.989, CI: 1.740-2.269, respectively) from the first to the second dose compared to Pfizer/BioNTech®. Conversely, the Moderna® vaccine appeared to offer a protective effect against HMB (OR: 0.852, CI: 0.771-0.939) and AM (OR: 0.861, CI: 0.790-0.937) between the second and third doses. These results were adjusted for potential confounders, such as age, previous COVID-19 infection, and other relevant covariates.
期刊介绍：
International Journal of Environmental Research and Public Health (IJERPH) (ISSN 1660-4601) is a peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications in the interdisciplinary area of environmental health sciences and public health. It links several scientific disciplines including biology, biochemistry, biotechnology, cellular and molecular biology, chemistry, computer science, ecology, engineering, epidemiology, genetics, immunology, microbiology, oncology, pathology, pharmacology, and toxicology, in an integrated fashion, to address critical issues related to environmental quality and public health. Therefore, IJERPH focuses on the publication of scientific and technical information on the impacts of natural phenomena and anthropogenic factors on the quality of our environment, the interrelationships between environmental health and the quality of life, as well as the socio-cultural, political, economic, and legal considerations related to environmental stewardship and public health.
The 2018 IJERPH Outstanding Reviewer Award has been launched! This award acknowledge those who have generously dedicated their time to review manuscripts submitted to IJERPH. See full details at http://www.mdpi.com/journal/ijerph/awards.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
